Cargando…
Preclinical and clinical data for factor Xa and “universal” reversal agents(,,)
Oral Factor Xa (FXa) inhibitors, a growing class of direct-acting anticoagulants, are frequently used to prevent stroke and systemic embolism in patients with atrial fibrillation and to prevent and treat venous thromboembolism. These drugs reduce the risk of clotting at the expense of increasing the...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568758/ https://www.ncbi.nlm.nih.gov/pubmed/27697443 http://dx.doi.org/10.1016/j.ajem.2016.09.052 |